Savara

134 articles about Savara

• Savara to Present at the Piper Sandler 35th Annual Healthcare Conference

  11/21/2023

  Savara Inc today announced that its management team will participate in a fireside chat at the Piper Sandler 35th Annual Healthcare Conference on November 28, 2023 at 1:00pm PT/4:00pm ET.

• Savara Reports Third Quarter Financial Results and Provides Business Update

  11/9/2023

  Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, reported financial results for the third quarter ending September 30, 2023 and provided a business update.

• Savara to Present at the Jefferies London Healthcare Conference 2023

  11/8/2023

  Savara Inc., a clinical stage biopharmaceutical company focused on rare respiratory diseases, announced that its management team will participate in a fireside chat at the Jefferies London Healthcare Conference on November 15, 2023 at 12:00pm GMT/7:00am EST.

• Savara Announces New Employment Inducement Grant - October 06, 2023

  10/6/2023

  Savara Inc., a clinical stage biopharmaceutical company focused on rare respiratory diseases, announced the grant of inducement awards to three new employees.

• Savara to Present at the H.C. Wainwright 25th Annual Global Investment Conference

  9/5/2023

  Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that its management team will present at the H.C. Wainwright 25th Annual Global Investment Conference on September 12, 2023 at 3:30pm ET/12:30pm PT.

• Savara Announces New Employment Inducement Grant - August 04, 2023

  8/4/2023

  Savara Inc., a clinical stage biopharmaceutical company focused on rare respiratory diseases, announced the grant of inducement awards to three new employees.

• Savara Announces Pricing of $80 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

  7/13/2023

  Savara Inc. today announced the pricing of an underwritten offering of 21,000,000 shares of its common stock at a price of $3.00 per share.

• Savara Completes Enrollment of Pivotal Phase 3 IMPALA-2 Trial of Molgramostim Nebulizer Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)

  6/26/2023

  Savara Inc. today announced that enrollment has been completed for the pivotal Phase 3 IMPALA-2 trial.

• Savara Added to Russell 3000® Index

  6/26/2023

  Savara Inc., a clinical stage biopharmaceutical company focused on rare respiratory diseases, announced that it has been added to the U.S. broad-market Russell 3000® Index at the conclusion of the Russell indexes annual reconstitution, effective upon the U.S. market open on Monday, June 26, 2023.

• Savara to Present at the 2023 Jefferies Healthcare Conference

  6/2/2023

  Savara Inc. announced that its management team will participate in a fireside chat at the Jefferies Healthcare Conference on June 9, 2023 at 10:30 am ET/7:30 am PT.

• Savara Reports First Quarter Financial Results and Provides Business Update

  5/15/2023

  Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, reported financial results for the first quarter ending March 31, 2023 and provided a business update.

• Savara Announces New Employment Inducement Grant - May 5, 2023

  5/5/2023

  Savara Inc. today announced the grant of inducement awards to two new employees.

• Savara Announces New Employment Inducement Grant - March 31, 2023

  3/31/2023

  Savara Inc., a clinical stage biopharmaceutical company focused on rare respiratory diseases, announced the grant of inducement awards to two new employees.

• Savara to Present at the Oppenheimer 33rd Annual Healthcare Conference

  3/6/2023

  Savara Inc. today announced that its management team will present at the Oppenheimer 33rd Annual Healthcare Conference on March 13, 2023 at 1:20pm ET.

• Savara Announces New Employment Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) - February 28, 2023

  2/28/2023

  Savara Inc., a clinical stage biopharmaceutical company focused on rare respiratory diseases, announced the grant of inducement awards to a new employee.

• Savara Announces New Leadership Appointments - February 14, 2023

  2/14/2023

  Savara Inc., a clinical stage biopharmaceutical company focused on rare respiratory diseases, announced the appointments of two pharmaceutical industry veterans to its executive leadership team.

• Savara Announces New Employment Inducement Grant - January 20, 2023

  1/20/2023

  Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to two new employees.

• Savara Announces New Employment Inducement Grant

  11/22/2022

  Savara Inc., a clinical stage biopharmaceutical company focused on rare respiratory diseases, announced the grant of an employee inducement award.

• Savara Reports Third Quarter 2022 Financial Results and Provides Business Update

  11/10/2022

  Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, reported financial results for the third quarter ending September 30, 2022 and provided a business update.

• Savara to Participate in Three Upcoming November 2022 Investor Conferences

  11/9/2022

  Savara Inc., a clinical stage biopharmaceutical company focused on rare respiratory diseases, announced that its management team will participate at the following investor healthcare conferences.